Hughes’ employment becomes effective Aug. 1, 2022, and he will be based out of Tel Aviv, Israel-based Teva’s U.S. headquarters in Parsippany, New Jersey.
Get the full story at our sister site, Drug Delivery Business News.
Teva Pharmaceuticals (NYSE:TEVA) shares ticked up this morning on fourth-quarter results that topped the consensus EPS forecast.
The Tel Aviv, Israel-based company posted losses of $159 million, or 14¢ per share, on sales of $4.1 billion for the three months ended Dec. 31, 2021, for a bottom-line slide into the red on a sales decline of 7.9%.
Get the full story at our sister site, Drug Delivery Business News.
Teva Pharmaceuticals (NYSE:TEVA) shares took a hit today on third-quarter results that fell short of the consensus forecast.
TEVA shares were down -4.7% at $8.95 per share in mid-morning trading. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down -0.8%.
Get the full story at our sister site, Drug Delivery Business News.
Teva Pharmaceuticals (NYSE:TEVA) initiated a voluntary recall of a lot of its Topotecan injection 4mg/4mL (1mg/mL) in the U.S.
The voluntary recall came as a result of a complaint received from a pharmacy after a single glass particle was observed inside one vial. Following further examination of the complaint sample, two other particulates were found and identified as one grey silicone particle and one translucent, colorless cotton fiber.
Get the full story at our sister site, Drug Delivery Business News.
Teva Pharmaceuticals (NYSE:TEVA) announced the U.S. launch of the first generic version of the twice-daily Perforomist inhalation solution.
Parsippany, N.J.-based Teva Pharmaceuticals — a U.S. affiliate of Tel Aviv, Israel-based Teva Pharmaceutical Industries Ltd. — launched the formoterol fumarate inhalation solution (20 mcg/2 mL) with an indication for treating bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Get the full story at our sister site, Drug Delivery Business News.
Teva Pharmaceuticals (NYSE:TEVA) shares stood firm before hours today on first-quarter earnings that topped the consensus forecast.
The Tel Aviv, Israel-based company posted profits of $84 million, or 7¢ per share, on sales of $4 billion for the three months ended March 31, 2021, for a more-than tripled bottom-line despite a sales decline of -8.6%.
Get the full story at our sister site, Drug Delivery Business News.
Teva Pharmaceuticals announced today that it received European marketing authorization for its Seffalair and BroPair Spiromax inhalers.
Seffalair Spiromax and its duplicate BroPair Spiromax (salmeterol xinafoate/ fluticasone propionate, 12.75/100 and 12.75/202 micrograms delivered doses) received approval as a maintenance treatment for asthma in adults and adolescents aged 12 years and older, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.
The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon.
Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means.
Among the best innovations in the space are some of the heavy-hitting companies, like Medtronic and Tandem Diabetes Care. Some up-and-comers are beginning to make waves, too, while research continues to uncover new ways to deliver therapeutics.
Here are eight types of drug delivery innovations you should know:
Next>>Despite plenty of ups and downs coming in the stock market for the medtech industry, there was hardly any movement from week to week.
MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.6 points at the end of last week (Aug. 21). Overall, medtech stocks saw a -0.2% decrease from the 89.77-point total at the same time a week prior (Aug. 14).
Once again, the index nearly reached a high point during the COVID-19 pandemic, as on Aug. 18, it hit 90.4 points for the second time in as many weeks, a total that nearly poked past the previous mid-pandemic high (90.45), which came on Aug. 5.
The most recent high mark represents just a -2.1% dip from the Feb. 19 high point of 92.32, while the tally at the end of the week marks a -2.9% decrease from that pre-pandemic high.
Meanwhile, the S&P 500 Index saw a 0.72% increase from Aug. 14 to Aug. 21, having reached record highs on Aug. 18. Meanwhil…
Massachusetts federal prosecutors today claimed that Teva Pharmaceuticals funneled $300 million from a pair of charitable foundations to subsidize Medicare copayments for a multiple sclerosis drug.
Teva Pharmaceuticals and Teva Neuroscience, the maker of Copaxone, simultaneously raised the drug’s price by 329%, allegedly violating the Anti-Kickback Statute and False Claims Act, according to the complaint filed by the U.S. Attorney’s Office in Boston.
The government alleges that Teva conspired with a specialty pharmacy, Advanced Care Scripts, Inc. (ACS), and two purportedly independent foundations, Chronic Disease Fund (CDF) and The Assistance Fund (TAF).
Get the full story on our sister site, Drug Discovery & Development.
Massachusetts federal prosecutors today claimed that Teva Pharmaceuticals funneled $300 million from a pair of charitable foundations to subsidize Medicare copayments for a multiple sclerosis drug.
Teva Pharmaceuticals and Teva Neuroscience, the maker of Copaxone, simultaneously raised the drug’s price by 329%, allegedly violating the Anti-Kickback Statute and False Claims Act, according to the complaint filed by the U.S. Attorney’s Office in Boston.
The government alleges that Teva conspired with a specialty pharmacy, Advanced Care Scripts, Inc. (ACS), and two purportedly independent foundations, Chronic Disease Fund (CDF) and The Assistance Fund (TAF).
When a Medicare beneficiary obtains a prescription drug covered by Medicare Part B or Part D, the beneficiary may be required to make a co-payment, which can be substantial for expensive medications. The Anti-Kickback Statute prohibits pharmaceutical companies from offering or paying, directl…
The Galien Foundation recently announced nominees for most innovative medical devices for its 14th Annual Prix Galien USA Awards.
The foundation bestows the Prix Galien Award annually to examples of outstanding biomedical and technology products that are designed to improve the human condition.
“As we celebrate 50 years of the Prix Galien process, we are honored to announce this year’s Prix Galien USA nominees, which represent the determination and passion for change that serves as the driving force of life-changing innovation,” said Sue Desmond-Hellmann, chair of the Prix Galien USA and Prix Galien International Committees, in a news release. “The awards committee applauds the nominees for their commitment to ensure a healthier future for generations to come.”
Get the full story on our sister site, Medical Design & Outsourcing.